TS-004524 — In engineered cardiovascular tissues, inhibiting purinergic signaling will promote high-quality neo tissue formation and prevent pathological remodeling. Inhibiting the P2Y12 receptor sustains a multitude of other necessary functions but prevents a detrimental excess.

TS-000416 — Factor XIII deficiency is a genetic bleeding disorder characterized by deficiency of clotting factor XIII resulting in prolonged, uncontrolled bleeding episodes. Unfortunately, the currently available, clinically-approved Factor XIII activity assays are technically challenging. Researchers at Nationwide Children’s Hospital have developed a new method for the determination of blood coagulation factor XIII enzymatic activity in a conventional enzyme-linked immunosorbent assay (ELISA). This method enables direct quantification of factor XIII as opposed to currently available indirect methods of measurement. This proof-of-principle technology provides improved, sensitive and simplified procedure for factor XIII estimation.